RUNX1 and hematologic disorder: To this end, RUNX1 inhibitors have been developed for the treatment of hematologic malignancies and may be repurposed for the treatment of PAH and recent studies have suggested several drugs that have potential to enhance SOX17 expression despite mutations in enhancer signal 1 and 2 (42).